MANHASSET, NY--North Shore University Hospital-Cornell University Medical College has announced the start of a phase I study of continuous infusion interleukin-2 given with a circadian modified pattern (CORN 9476).
M. Margaret Kemeny, MD, chief, division of surgical oncology, said that the trial is open to all patients with metastatic melanoma or metastatic renal cell carcinoma except those who have already received previous IL-2 therapy or have failed two or more chemotherapeutic or immunotherapeutic treatments.
The goals of the study are (1) to identify the optimal cycle in a 24-hour period for the administration of IL-2 as a continuous infusion and (2) to determine whether increased amounts of IL-2 are tolerated with less toxicity using this optimal pattern. For more information, contact Dr. Kemeny at 516-562-3153.
